Nuveen Asset Management LLC Grows Stock Position in Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX)

Nuveen Asset Management LLC increased its holdings in shares of Recursion Pharmaceuticals, Inc. (NASDAQ:RXRXGet Rating) by 49.0% during the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 847,137 shares of the company’s stock after buying an additional 278,555 shares during the quarter. Nuveen Asset Management LLC owned about 0.49% of Recursion Pharmaceuticals worth $9,014,000 as of its most recent filing with the Securities and Exchange Commission.

Several other large investors have also recently added to or reduced their stakes in the business. Rockefeller Capital Management L.P. lifted its position in Recursion Pharmaceuticals by 23.2% during the third quarter. Rockefeller Capital Management L.P. now owns 7,319 shares of the company’s stock worth $77,000 after buying an additional 1,378 shares during the period. Baldwin Brothers LLC MA increased its stake in Recursion Pharmaceuticals by 100.0% during the third quarter. Baldwin Brothers LLC MA now owns 5,502 shares of the company’s stock worth $59,000 after acquiring an additional 2,751 shares during the last quarter. UBS Asset Management Americas Inc. increased its stake in Recursion Pharmaceuticals by 6.8% during the second quarter. UBS Asset Management Americas Inc. now owns 51,453 shares of the company’s stock worth $419,000 after acquiring an additional 3,259 shares during the last quarter. Albion Financial Group UT increased its stake in Recursion Pharmaceuticals by 3,385.0% during the third quarter. Albion Financial Group UT now owns 4,182 shares of the company’s stock worth $44,000 after acquiring an additional 4,062 shares during the last quarter. Finally, CWM LLC increased its stake in Recursion Pharmaceuticals by 99.3% during the third quarter. CWM LLC now owns 8,990 shares of the company’s stock worth $96,000 after acquiring an additional 4,480 shares during the last quarter. 63.62% of the stock is currently owned by hedge funds and other institutional investors.

Insider Activity

In other news, CEO Christopher Gibson sold 70,890 shares of the stock in a transaction dated Wednesday, March 8th. The stock was sold at an average price of $8.10, for a total value of $574,209.00. Following the completion of the sale, the chief executive officer now owns 963,787 shares in the company, valued at $7,806,674.70. The transaction was disclosed in a legal filing with the SEC, which is available through this link. In other Recursion Pharmaceuticals news, COO Tina Marriott Larson sold 8,000 shares of the firm’s stock in a transaction that occurred on Thursday, December 29th. The stock was sold at an average price of $7.70, for a total transaction of $61,600.00. Following the completion of the sale, the chief operating officer now owns 203,654 shares in the company, valued at approximately $1,568,135.80. The sale was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, CEO Christopher Gibson sold 70,890 shares of the firm’s stock in a transaction that occurred on Wednesday, March 8th. The shares were sold at an average price of $8.10, for a total value of $574,209.00. Following the sale, the chief executive officer now owns 963,787 shares of the company’s stock, valued at approximately $7,806,674.70. The disclosure for this sale can be found here. Over the last quarter, insiders purchased 581,017 shares of company stock worth $4,440,853 and sold 221,571 shares worth $1,799,332. Insiders own 22.25% of the company’s stock.

Recursion Pharmaceuticals Stock Performance

RXRX stock opened at $7.07 on Friday. Recursion Pharmaceuticals, Inc. has a 1 year low of $4.92 and a 1 year high of $14.18. The firm has a market cap of $1.35 billion, a P/E ratio of -5.16 and a beta of -0.33. The stock has a 50-day simple moving average of $8.21 and a 200-day simple moving average of $9.52.

Recursion Pharmaceuticals (NASDAQ:RXRXGet Rating) last posted its earnings results on Monday, February 27th. The company reported ($0.31) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.15) by ($0.16). Recursion Pharmaceuticals had a negative net margin of 601.05% and a negative return on equity of 53.07%. The company had revenue of $13.68 million during the quarter, compared to analyst estimates of $66.68 million. On average, equities research analysts predict that Recursion Pharmaceuticals, Inc. will post -1.23 EPS for the current year.

Analyst Ratings Changes

Separately, SVB Leerink dropped their price target on Recursion Pharmaceuticals from $9.00 to $8.00 and set a “market perform” rating for the company in a research note on Monday, January 23rd.

Recursion Pharmaceuticals Profile

(Get Rating)

Recursion Pharmaceuticals, Inc operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase IIa clinical trial to treat cerebral cavernous malformation; REC-2282 for the treatment of neurofibromatosis type 2; REC-4881 to treat familial adenomatous polyposis; and REC-3599, which is in Phase I clinical trial to treat GM2 gangliosidosis.

See Also

Want to see what other hedge funds are holding RXRX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Recursion Pharmaceuticals, Inc. (NASDAQ:RXRXGet Rating).

Institutional Ownership by Quarter for Recursion Pharmaceuticals (NASDAQ:RXRX)

Receive News & Ratings for Recursion Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Recursion Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.